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Abstract: Current treatments have failed to stem the continuing rise in health care resource 
use and fatalities associated with exacerbations of chronic obstructive pulmonary disease 
(COPD). Reduction of severity and prevention of new exacerbations are therefore important 
in disease management, especially for patients with frequent exacerbations. Acute exacerba-
tion treatment includes short-acting bronchodilators, systemic corticosteroids, and antibiotics 
if bacterial infections are present. Oxygen and/or ventilatory support may be necessary for 
life-threatening conditions. Rising health care costs have provided added impetus to find novel 
therapeutic approaches in the primary care setting to prevent and rapidly treat exacerbations 
before hospitalization is required. Proactive interventions may include risk reduction measures 
(eg, smoking cessation and vaccinations) to reduce triggers and supplemental pulmonary reha-
bilitation to prevent or delay exacerbation recurrence. Long-term treatment strategies should 
include individualized management, addressing coexisting nonpulmonary conditions, and the 
use of maintenance pharmacotherapies, eg, long-acting bronchodilators as monotherapy or in 
combination with inhaled corticosteroids to reduce exacerbations. Self-management plans that 
help patients recognize their symptoms and promptly access treatments have the potential to 
prevent exacerbations from reaching the stage that requires hospitalization.
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Introduction
Exacerbations of chronic obstructive pulmonary disease (COPD) manifest as aggra-
vated respiratory symptoms that can negatively impact a patient’s disease trajectory, 
often with grim consequences to the individual and society. The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) defines exacerbations as “an event in 
the natural course of the disease characterized by a change in the patient’s baseline 
dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute 
in onset, and may warrant a change in regular medication.”1 Variations in defining, 
reporting, or diagnosing episodes may mask the true health and economic burden of 
exacerbations. Nevertheless, exacerbations are expected to increase in tandem, with 
projections that deaths from underlying COPD will rise by more than 30% over the 
next decade without interventions to cut risks.2 Compounding the societal health 
impact are the staggering costs involved in treating acute exacerbations, especially if 
they are severe in nature and therefore warrant hospitalization. The total cost of caring 
for COPD in the United States is rapidly approaching US$50 billion per year. Most 
estimates suggest that 70% of that cost relates to treating exacerbations, particularly 
severe episodes requiring hospitalization and often intensive care.3International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Exacerbation-prone individuals may be negatively 
affected in terms of a decreased quality of life, increased 
hospitalization, and premature deaths, either as a conse-
quence of COPD or coexisting diseases.4 Exacerbation 
frequencies and associated hospitalizations in those who 
are prone to exacerbations typically range from 0.5 to 5.2 
exacerbations (depending on definitions used) and from 0.09 
to 2.40 hospitalizations per year, respectively.5–7 Patients with 
severe COPD who have frequent exacerbations (# 6-month 
intervals; . three per year) have a more rapid decline in lung 
function and worse health-related quality of life than those 
who experience infrequent exacerbations.8 However, data 
from the Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints (ECLIPSE) initiative sug-
gest that there is a frequent-exacerbation phenotype that is 
independent of disease severity.9 Exacerbation duration is 
variable but may last up to 5 weeks,10 and the impact can be 
prolonged or permanent;11 there is also a high risk of a recur-
ring exacerbation in the 8-week period following an index 
event.12 The devastating consequences of exacerbations are 
underscored by high rates of relapse (22%–32% of emergency 
department patients visit the department again),13 1-year 
(25%) and 5-year (44%) hospital readmissions,14 and overall 
treatment failures (32%),15 as well as high exacerbation-
related fatalities (2.5%–10.0%), increasing in intensive care 
unit patients to 20%–24%.16,17
Reports are beginning to illuminate the gap between 
guideline-recommended and actual treatment and follow-up 
care of hospitalized COPD patients. One retrospective analy-
sis of these patients showed that prescribed respiratory drugs 
were underused, overused, or misused.18 A separate retrospec-
tive cohort study showed that hospitalized patients with acute 
exacerbations received adequate care, but that there were 
opportunities to improve treatment in both the inpatient and 
outpatient settings.19 Recognition of the cost-prohibitive 
nature and frequent treatment of recurrent exacerbations 
in hospitals has added to the interest in treating milder or 
frequent episodes in the primary care setting. Ultimately we 
will need to balance the cost of potential preventive therapies 
versus the benefit of preventing exacerbations. The aim of 
this review is to describe strategies that may improve the 
prevention and treatment of exacerbations.
Triggers and effects of COPD 
exacerbations
The transition from stable-state COPD to onset of an exac-
erbation typically involves amplified airway inflammation.1 
Infections of the tracheobronchial tree (viral and bacterial), 
exposure to air pollution (eg, inhalation of tobacco smoke, 
occupational and environmental exposure to particulates or 
noxious gases), and suboptimal treatment adherence account 
for most identifiable causes of exacerbations.1 Exacerbations 
triggered by respiratory viral mono- or coinfections are more 
likely to be severe, prolonged, and associated with hospital 
admissions compared with episodes where respiratory viruses 
were not detected. Further investigation is needed to establish 
whether chronic respiratory viral infection of stable COPD 
patients’ airways predisposes patients to exacerbations.20 Many 
exacerbations are triggered by a bacterial infection caused by, 
for example, Streptococcus pneumoniae,  Haemophilus influ-
enzae, Moraxella catarrhalis, and Pseudomonas aeruginosa.20 
Elevated levels of the latter pathogen are more likely to be 
associated with severe COPD or when systemic steroids and/
or antibiotics had been prescribed in the preceding months.21 
In addition, Bordetella pertussis, the re-emergent pathogen 
responsible for pertussis (whooping cough), has been associ-
ated with 31% of acute exacerbations of chronic bronchitis, 
according to one pilot study.22 While infections are the most 
common cause of exacerbations,1 the apparent increased 
susceptibility to this etiologic factor in patients with COPD is 
not well understood. Recent evidence suggests that an altered 
airway epithelial cell phenotype may contribute to increased 
susceptibility to viral infection in patients with COPD com-
pared with control subjects.23
Exacerbations may also increase the risk of nonpul-
monary events and related mortality. Specific molecular 
pathways culminating in exacerbations remain to be eluci-
dated, but elevated systemic inflammatory markers are often 
present during acute exacerbations and have been associated 
with a small but statistically significant risk of stroke and 
  cardiovascular events.24 Worsening bronchoconstriction 
from an exacerbation may elevate pulmonary artery pres-
sures, placing an increased burden on the right side of the 
heart.24 A higher post-exacerbation myocardial infarction 
incidence has been reported in patients with more frequent 
exacerbations, although the reasons for this finding remain 
unclear.24 The recent ECLIPSE study showed that more 
frequent exacerbations were also associated with greater 
impairment in health status.9
Patients who have frequent exacerbations have been 
defined as having more than the annual median number of 
episodes for a given study, usually two steroid- and/or anti-
biotic-requiring or three symptom-defined exacerbations.20 
These patients can exhibit elevations in specific blood and 
airway-derived biomarkers compared with those who have 
infrequent exacerbations,25,26 generally have a faster decline International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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in functional status,27 are more prone to rehospitalization,14 
and are more likely to be housebound20 than those who 
have infrequent exacerbations. Patients hospitalized with 
COPD exacerbations are also more likely to have coexisting 
pneumonia and diabetes than hospitalized patients without 
COPD.28
Diagnosis of an exacerbation
Diagnosis and staging of COPD exacerbations depend on 
symptom-based criteria and/or health care resource utiliza-
tion (Table 1). Since increasing confusion may be part of 
respiratory compromise, it may also be beneficial to assess 
a patient’s mental status during evaluation (Table 2). Of the 
known hospitalization indicators, escalating respiratory dis-
tress, onset of respiratory acidosis, significant   nonpulmonary 
conditions, and the need for ventilatory (invasive or 
  noninvasive mechanical) support are especially important, 
since they are associated with an increased risk of death.1
While a severe exacerbation is almost always identified 
and treatment provided, many milder events go unreported 
by patients29 or are labeled by clinicians as upper respira-
tory tract infections or acute bronchitis. Recognizing and 
appropriately treating all exacerbations, including milder 
symptom worsening reported by patients, may help prevent 
future exacerbations. Composite indices can help identify 
patients at increased risk of developing a future exacerbation. 
Examples include indices for (1) BODE (body mass index, 
airflow obstruction [forced expiratory volume in 1 second 
(FEV1)], dyspnea, and exercise capacity)30 and (2) DOSE 
(dyspnea scale, airflow obstruction [FEV1], smoking status 
[current versus former], and prior exacerbation frequency).31 
In addition, the Exacerbations of Chronic Pulmonary Disease 
Tool, a Patient-Reported Outcome measure initiative, has 
been designed to standardize evaluations of the frequency, 
severity, and duration of acute exacerbations of COPD and 
chronic bronchitis. A recent observational study suggests that 
this 14-item digital diary is reliable, valid, and sensitive to 
change with exacerbation recovery.32
Since no single test can fulfill all requirements, additional 
evaluations are needed to accurately identify exacerbation-
prone patients. Inadequate recording of relevant factors 
(medical history, risk factors, exercise tolerance), lack of 
equipment, clinicians with limited training, as well as patients 
with multiple chronic conditions may further complicate 
diagnosis.
Investigational biomarkers associated with exacerbation 
etiology, severity, and recovery can potentially augment 
the current diagnostic toolkit. One example is the hormone 
precursor procalcitonin, which is elevated in serum when 
bacterial infections are present.33 Ongoing studies are needed 
to assess the routine use of procalcitonin to diagnose these 
exacerbations (in order to reduce patient exposure to antibi-
otics); its use has not yet been recommended by guidelines. 
Further studies are also needed to assess the value of routine 
testing for biomarkers found in association with exacerba-
tions, such as fractional exhaled nitric oxide and C-reactive 
protein (CRP).33–35
Treatment of acute exacerbations
Given the frequently fatal nature of COPD exacerbations, 
they must be recognized early and accurately to allow prompt 
initiation of therapy. Early detection and treatment of exac-
erbations can improve patients’ wellbeing and health-related 
quality of life and reduce hospitalizations.1 The recom-
mended treatment algorithm for exacerbations is delineated 
in Figure 1.1,36,37 Pharmacotherapy is intended to relieve 
dyspnea, reduce airway inflammation, improve lung func-
tion, and eradicate infections, potentially moderating disease 
progression. A reliable predictor of a recurrent exacerbation 
is a history of previous exacerbations.6,9
Bronchodilators
The first step in the treatment of an exacerbation is to increase 
the dose of inhaled bronchodilator to decrease   dyspnea.1 
Short-acting β-agonists (SABAs) are used as needed 
because they have a rapid onset of action on bronchocon-
striction. Prescriptions of these bronchodilators are subject 
to consideration of known adverse events for SABAs (eg, 
hypokalemia).1 Combining SABAs with inhaled short-acting 
anticholinergics (SAACs) may have additional benefit. Com-
mon side effects of anticholinergics include dry mouth and 
Table 1 Commonly used definitions of exacerbation severity33,34
Exacerbation symptoms
• Increase in dyspnea 
• Change in sputum volume 
• Change in sputum purulence
Degree of exacerbation  
(number of symptomsa)
Feature
Mild (1 of 3 present) Symptomsb can be controlled by 
increasing prescribed medication dose
Moderate (2 of 3 present) Symptomsb require corticosteroids 
and/or antibiotics
Severe (all 3 present) Symptoms need evaluation in a 
hospital/eD/intensive care unit
Notes: aBeyond periodic variability necessitating a change in medical management; 
bTreatment in a primary care setting is sufficient for patients with few comorbidities.
Abbreviation: eD, emergency department.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Hospitalization indicators and evaluations of exacerbations1
General indications for hospitalization
• Frequent episodes
• Diagnostic uncertainty
• Advanced age
• Change in mental status
• Symptoms that are poorly responsive to current treatment
• Advanced COPDa
• Little or no psychosocial support
•   Intensive care is warranted for life-threatening episodes associated with: respiratory failure; shock; hemodynamic instability; hypoxic renal, hepatic, 
or brain dysfunction
Symptomatic indications and diagnostic tests
Indicationb Diagnostic test
•   exposure to risk factors (genetic predisposition; inhalation of tobacco  
smoke or environmental pollutants) and/or low exercise tolerance
–   Accurate recording of medical history and risk factors, preferably 
aided by validated questionnaires, can identify undiagnosed 
COPD cases
•   Intensified respiratory symptoms (cough, sputum production,  
and dyspnea)
–   Baseline spirometry (Fev1/FVC) is useful to confirm COPD, but 
is not indicated for patients during an episode
–   Pulse oximetry is indicated for all patients, especially in the case 
of severe episodes
• Change in sputum volume and appearance 
• Lethargy, fever, fatigue
–   Confirm presence of bacterial infections with sputum culture or 
molecular typing
• elevation of jugular venous pressure and pitting ankle edema – Confirm suspected right heart failure with radiography
• Signs of respiratory failurec 
• SaO2 , 92%
– Quantify hypercarbia or hypoxemia with ABG testing
• Chest discomfort If unresponsive or poorly responsive to conventional exacerbation 
treatment: 
–   Identify non-COPD (eg, cardiac arrhythmia, ischemia) causes  
of dyspnea with radiography, cardiac enzyme  
(for suspected ischemia), and brain natriuretic peptide  
(for CHF) measurements
– Consider nonadherence to prescribed treatment
• Metabolic disorder –   Laboratory tests for alterations in glycemia, acid-base balance, 
electrolytes
• Current smokers 
• Underutilization or poor response to long-term oxygen treatment.
–   Hematocrit . 55% associated with polycythemia and arterial 
hypoxemia (usually seen in current smokers)
–   Low hematocrit indicative of poor prognosis in patients with 
severe COPD receiving long-term oxygen treatment; consider 
complications such as pulmonary embolism or edema
Notes: aFev1/FvC , 70%; Fev1 , 50% with respiratory symptoms either at rest or upon minimal exertion; bIndications with or without a prior COPD diagnosis may warrant 
several evaluations. There could potentially be a reciprocal and causal relationship between COPD and nonpulmonary conditions. examples of the latter conditions include 
cardiovascular diseases, stroke, pneumonia, sepsis, diabetes mellitus, and renal or hepatic failure; cPaO2 , 8.0 kPa with or without PaCO2.
Abbreviations: ABG, arterial blood gas; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in 1 second; FvC, 
forced vital capacity; Pa, partial pressure; Sa, saturation.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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constipation.38 If patients are already receiving maintenance 
pharmacotherapies, some caution needs to be exercised when 
adding regular doses of SABAs or SAACs, since side effects 
could increase. Methylxanthine derivatives may play a role 
as second-line therapies in selected cases where patients are 
poorly responsive to SABAs or SAACs;1 however, their 
significant potential side effects when used in high doses 
or combined with other common chronic disease therapies 
warrant close clinical and biochemical monitoring for pos-
sible adverse events.
Corticosteroids
The major use for systemic steroids is in combination 
with other therapies, eg, bronchodilators, during an acute 
  exacerbation.1 No steroid taper is required for a short course of 
systemic steroid therapy, per GOLD guidelines.1 Recent data 
suggest that oral corticosteroids are as effective as intravenous 
corticosteroids in patients hospitalized with exacerbations; 
however, prolonged treatment with oral corticosteroids 
(.10 days) does not result in greater efficacy and increases 
the risk of side effects such as hyperglycemia and muscle 
atrophy.1 While an approved inhaled   corticosteroid (ICS)/long-
acting β-agonist (LABA) combination is used in the context 
of preventing the next exacerbation, the GOLD guidelines 
state that the ICS, budesonide, “alone, or in combination with 
formoterol may be an alternative (although more expensive) to 
oral glucocorticosteroids in the treatment of exacerbations.”1
Antibiotics
Bacterially triggered exacerbations are usually amenable to 
appropriate antibiotic therapy.1 Current antibiotic recommen-
dations (Table 3) will depend on the bacterial strains that are 
responsive or resistant to antimicrobial therapies. Relevant 
factors that may guide specific antibiotic choices are drug 
One or more symptoms
• Increase in dyspnea, change in sputum volume, change in sputum purulence; oxygen or
   ventilatory support at any stage in presence of new or established respiratory failure
Mild or moderate exacerbations
• Increase dose/frequency of
   short-acting bronchodilators
Patient recovers
• Long-term
   treatment review
Patient does not recover
• Add oral
   corticosteroid
Patient continues to deteriorate
• Exclude complications
Discharge and follow-up
• Maintenance therapies
• Pulmonary rehabilitation
• Assess ability to cope at home
• Assess need for home nebulizer
   for patients with severe COPD
Severe exacerbations
• Hospitalize if signs of respiratory
   failure or significant nonpulmonary
   conditions are present
Manage
nonpulmonary
conditions • Consider antibiotics if bacterial
   infections are present
Figure 1 Treatment algorithm for patients with exacerbations. 
Adapted from the Global Initiative for Chronic Obstructive Lung Disease guidelines,1 Anthonisen et al,36 and Celli et al.37 
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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penetration into pulmonary airways, efficacy of microbial 
clearance, treatment duration, likelihood of pathogen recur-
rence, and any drug-related adverse events.39
Adding antibiotics to corticosteroid therapy has been 
shown to prolong the time to the next exacerbation and to 
reduce the risk of a new exacerbation versus corticosteroid 
use alone.40 One meta-analysis showed that treatment dura-
tion (# 5 days) did not affect the cure rates attributed to 
broad-spectrum antibiotics,41 whereas another meta-analysis 
showed a lower risk of treatment failure for broad-spectrum 
versus narrow-spectrum antibiotics.42 A randomized trial of 
a broad spectrum antibiotic, doxycycline, added to systemic 
corticosteroids in selected patients hospitalized with acute 
exacerbations of COPD (AECOPD), demonstrated similar 
clinical success on day 30 in intent-to-treat (odds ratio 1.3, 
95% confidence interval [CI] 0.8–2.0) and per-protocol 
patients, but on day 10 those receiving doxycycline dem-
onstrated improvement in symptom score, microbiologic 
outcome, and clinical cure.43 In this study, patients with 
higher CRP levels treated with antibiotics had a better 
response than those in the placebo group, suggesting a 
potential future importance for this biomarker in defining 
therapeutic paths.
Oxygen and noninvasive ventilation
Oxygen requirements typically increase during exacerba-
tions. Oxygen supplementation and/or ventilation should 
be considered for patients who are experiencing signs of 
respiratory failure (eg, worsening hypercapnia, hypoxemia, 
acidosis, or pulmonary embolism) or have coexisting condi-
tions such as myocardial infarction or sepsis.44 Long-term 
oxygen therapy (indicated if saturation level is below 88%) 
can correct hypoxemia in patients with very severe COPD 
and improve overall health status.1 If the patient is discharged 
from the hospital on oxygen or on higher amounts of oxy-
gen than on admission, the oxygen requirement must be 
reevaluated as the patient improves, in order to better define 
long-term requirements.
If patients with severe exacerbations are poorly 
responsive to oxygen supplementation alone, they may 
Table 3 Antibiotic treatment in exacerbation of COPD
COPD exacerbation  
indicationa,b
Oral treatmentc Alternative oral  
treatmentc
Parenteral treatmentc
Group A 
(mild exacerbation: no risk  
factors for poor outcome)
Patients with only one cardinal  
symptomd should not receive antibiotics 
If indication then: 
•   β-lactam (penicillin, ampicillin/ 
amoxicilline)
• Tetracycline 
• Trimethoprim/sulfamethoxazole
•   β-lactam/β-lactamase  
inhibitor (co-amoxiclav)
•   Macrolides (azithromycin,  
clarithromycin,  
roxithromycinf)
•   Cephalosporins – second  
or third generation
• Ketolides (telithromycin)
Group B 
(moderate exacerbation  
with risk factor(s) for poor  
outcome)
•   β-lactam/β-lactamase inhibitor  
(co-amoxiclav)
•   Fluoroquinolonesf  
(gemifloxacin, levofloxacin,  
moxifloxacin)
•   β-lactam/β-lactamase  
inhibitor (co-amoxiclav,  
ampicillin/sulbactam)
•   Cephalosporins (second  
or third generation)
•   Fluoroquinolonesf  
(levofloxacin, moxifloxacin)
Group C 
(severe exacerbation with risk  
factors for Pseudomonas  
aeruginosa infection)
In patients at risk for Pseudomonas  
infections: 
•   Fluoroquinolonesf (ciprofloxacin,  
levofloxacin – high doseg)
•   Fluoroquinolonesf  
(ciprofloxacin, levofloxacin  
– high doseg)
•   β-lactam with P. aeruginosa activity
Notes: Relevant risk factors: presence of comorbid diseases, severe COPD, frequent exacerbations (.3/year), and antimicrobial use in the last 3 months. aAll patients with 
symptoms of a COPD exacerbation should be treated with additional bronchodilators ± glucocorticosteroids; bClasses of antibiotics are provided (with specific agents in 
parentheses); cNo particular order. dCardinal symptoms are increased: dyspnea, sputum volume, and sputum purulence; eThis antibiotic is not appropriate in areas where 
there is increased prevalence of β-lactamase producing Haemophilus influenzae and Moraxella catarrhalis and/or of Streptococcus pneumoniae resistant to penicillin;  fNot 
available in all areas of the world; gDose 750 mg effective against Pseudomonas aeruginosa. Reproduced with permission.1 Global Initiative for Chronic Obstructive Lung Disease 
(GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD [updated December 2010]. Available from: http://www.goldcopd.org/Guidelineitem.
asp?l1=2&l2=1&intId=989. Accessed April 13, 2011.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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be candidates for ventilatory support to avoid intubation, 
including noninvasive ventilation (NIV) in the case of 
eligible individuals.1 Although the prognosis is poor for all 
patients requiring ventilatory support, evidence based on 
data from a subset of patients suggests that NIV reduces 
morbidity and mortality rates and intensive care unit or 
hospital lengths of stay.45
Reduction/prevention  
of exacerbations
Although patients hospitalized with severe exacerbations 
usually receive recommended care, most patients are not 
discharged with appropriate support and medications.19 It is 
debatable whether health care insurances will continue to 
pay for potentially avoidable COPD-related hospital read-
missions. Thus, there is a growing impetus to prevent or 
reduce exacerbation severity in the primary care outpatient 
setting to avoid hospitalization. Patients with exacerbations 
may benefit from risk reduction measures and maintenance 
pharmacotherapies, supplemented with self-management 
plans, as part of pulmonary rehabilitation (PR).
Risk reduction
Results from a large-scale retrospective analysis of cur-
rent and former smokers showed that smoking cessation 
significantly reduced exacerbations after adjusting for age, 
comorbidities, disease severity, and socioeconomic status 
(adjusted hazard ratio [HR] 0.78, 95% CI 0.75–0.87).46 
These data support guideline recommendations for smok-
ing cessation as a risk reduction measure regardless of 
disease status.1
Seasonal influenza and pneumococcal pneumonia 
  vaccinations should be standard, as appropriate for COPD 
patients, according to the GOLD guidelines.1 Elderly COPD 
patients (aged $ 65 years), in particular, suffer significant 
adverse events from influenza and derive health benefits 
from vaccinations in the form of fewer hospitalizations, 
outpatient visits, and fatalities. Immunizations in this high-
risk group should, therefore, be a priority for all clinicians.47 
Consideration should also be given to providing a one-time 
dose of the tetanus-diphtheria-acellular-pertussis (Tdap) 
vaccine to previously unvaccinated individuals with COPD 
(aged , 65 years), based on medical and other indications;48 
for example, in the face of a pertussis epidemic in local chil-
dren. The Advisory Committee on Immunization Practices 
recommends Tdap for older individuals (aged $ 65 years) 
not previously immunized with this vaccine who anticipate 
close contact to infants (aged , 12 months).48,49
Antibiotic prophylaxis with a low-dose macrolide has 
emerged as another possible therapeutic option for reduc-
ing exacerbation frequency. In a 12-month study of COPD 
patients experiencing moderate and/or severe exacerba-
tions (35% experienced three or more exacerbations in 
the year before recruitment), twice-daily administration of 
erythromycin, was associated with a significant reduction 
in exacerbations compared with placebo.50 Results from a 
prospective, randomized, double-blind, placebo-controlled 
trial showed that long-term, once-daily administration 
of azithromycin, in addition to usual care, decreased the 
frequency of AECOPD (1.47 versus 1.84/patient-year, 
P = 0.004) and improved the quality of life of exacerbation-
prone COPD patients.51
Maintenance pharmacotherapies
Results from two megatrials, Understanding Potential Long-
term Impacts on Function with Tiotropium (UPLIFT®)52 and 
Towards a Revolution in COPD Health (TORCH),53 have 
shown a benefit for a long-acting anticholinergic (LAAC), 
tiotropium, and a LABA/ICS combination (salmeterol/ 
fluticasone) in reducing key clinical endpoints, including 
exacerbations. The United States Food and Drug Administra-
tion (FDA) has approved tiotropium to reduce exacerbations 
in COPD patients and salmeterol/fluticasone to reduce exac-
erbations in COPD patients with a history of exacerbations. 
In the UPLIFT trial, median time to the first exacerbation 
was 16.7 months (95% CI 14.9–17.9) in the tiotropium group 
versus 12.5 months (95% CI 11.5–13.8) in the placebo group 
(HR 0.86, 95% CI 0.81–0.91). Tiotropium treatment was 
also associated with a 14% decrease in the mean number of 
exacerbations versus placebo (P , 0.001).52
A study by Niewoehner et al showed tiotropium reduced 
the proportion of patients with moderate to severe COPD 
experiencing exacerbations and may reduce health care 
utilization compared with placebo.54 In this study, the 
treatment groups received “usual care” as well as study 
treatment that could include respiratory medications other 
than anticholinergic bronchodilators, which may reflect 
“real-world” practice.54 In the 3-year TORCH study, salme-
terol/fluticasone (50 µg/500 µg) treatment versus placebo 
resulted in a rate ratio for exacerbations of 0.75 (95% CI 
0.69–0.81; P , 0.001), which is a reduction of 25% in 
affected in  dividuals.53 Another 1-year study showed that 
treatment with salmeterol/fluticasone (50 µg/250 µg) 
reduced exacerbation rates in patients with moderate to 
severe COPD by 30.5% compared with salmeterol.55 A direct 
comparison of tiotropium (18 µg) and salmeterol/fluticasone International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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(50 µg/500 µg) in patients with severe to very severe COPD 
showed no statistical difference in exacerbation rates over 2 
years.56 However, tiotropium (18 µg) was more effective than 
salmeterol (50 µg) in all assessed exacerbation endpoints 
and across all the major subgroups, according to a separate 
1-year comparative study of only the LAAC and LABA given 
to patients with moderate to severe COPD and a history of 
exacerbations.57
Another LABA/ICS combination, budesonide/for-
moterol (not FDA-indicated for COPD exacerbations), 
administered to patients with moderate to severe COPD, 
reduced systemic steroid-requiring exacerbations versus 
formoterol alone in a 6-month study (20%–25% exacer-
bation reductions with budesonide-containing treatments 
versus formoterol or placebo alone).58 Similarly, a 1-year 
study of the treatment effects of these agents showed 
25%–29% lowered exacerbation rates (with budesonide-
containing therapies) beyond reductions achieved with 
formoterol alone.59 In addition, budesonide/formoterol 
plus tiotropium specifically reduced the number of exac-
erbations by 62% versus tiotropium treatment alone.60 
Roflumilast, an oral phosphodiesterase-4 inhibitor, is 
indicated in the United States as a treatment to reduce 
the risk of COPD exacerbations in patients with severe 
COPD associated with chronic bronchitis and a history 
of exacerbations (up to 18% exacerbation reduction noted 
in studies).61
Adherence
Adherence to disease management guidelines by clini-
cians and individualized patient education to optimize 
adherence to medications and nonpharmacological 
treatments may be key factors in lowering exacerbation 
rates. Suboptimal medication adherence, whether as a 
consequence of patient-specific factors (costs, physi-
cal or psychosocial factors, or insufficient ed  ucation by 
the physician),62–64 less-than-optimal im  plementation of 
  gu  ideline-recommended therapy by physicians,65 or polyp-
harmacy due to comorbidities,64 remains a tremendously 
important issue. Prescribing appropriate treatment regimens 
can only be effective if the patient continues to take their 
medication. In a survey of over a 1000 COPD patients, 
50% had 6–10 comorbidities, over 30% were receiving 
5–10 non-COPD medications, and over 20% were receiv-
ing over 11 non-COPD medications.64 Inhaler misuse may 
also contribute to suboptimal medication adherence.66 It is 
important for   clinicians to keep all these factors in mind, 
since adherence to inhaled COPD medications has been 
correlated with reduced hospital admissions and mortality 
risk due to exacerbations.1
Pulmonary rehabilitation
PR as an adjunctive therapy can improve dyspnea, exercise 
tolerance, and health-related quality of life, as well as reduce 
recurrent exacerbations and, hence, the risk of hospitalization 
in some patients.1 Stage-appropriate PR should include one 
or more aspects of disease and inhaler education, optimiza-
tion of daily living activities, self-management of symptoms, 
anxiety and stress control, oxygen therapy, guidance for early 
detection and treatment of COPD exacerbations, smoking 
cessation, nutrition, structured exercise, and increased physi-
cal activity at home.67 A systematic review has shown that 
PR has the potential to reduce the number of exacerbations 
and associated hospital visits as well as their severity.68 In 
a multicenter study, tiotropium plus PR-treated patients 
experienced fewer exacerbations and exacerbation days, and 
improvements in health-related quality of life, relative to 
the tiotropium-only group.69 Clinically meaningful changes 
in exercise tolerance, dyspnea, and fatigue were observed 
in United Kingdom patients treated for exacerbations in a 
hospital setting and enrolled 10 days post discharge in an 
8-week PR program (10% of rehabilitated patients versus 
42% of usual-care patients; P = 0.01). Shuttle-walk distance 
was nearly doubled in rehabilitated patients, and dyspnea and 
fatigue were significantly reduced.70
Beginning PR after resolution of an acute exacerbation 
resulted in reduced health care utilization and costs in a 
separate United States study.71 Since this is, in essence, a 
behavioral intervention, durable health benefits can be reaped 
only if a patient can sustain behavior and lifestyle changes 
over the long term.
Cardiac protective therapies
Cardiovascular events are extremely common in COPD patients 
and impact morbidity and mortality.64,72,73 These   diseases 
cause 25% of deaths and nearly 50% of   hospitalizations in 
patients with mild to moderate COPD, as well as signifi-
cantly increasing the duration of hospitalization and risk of 
premature death in patients with severe exacerbations.73,74 It 
has also been suggested that all patients who have frequent 
exacerbations may need treatments to reduce cardiovascular 
events during stable disease periods.75
European guidelines state that COPD is not a contraindica-
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β-blockers;76 however, their underuse in COPD has classically 
been associated with concern over the risk of worsening 
bronchospasm. Emerging evidence suggests that treatment 
with cardioselective β-blockers is safe, well tolerated, and 
reduces the risk of exacerbations and premature deaths in 
COPD patients with coexisting cardiovascular disease.77,78 In 
the absence of larger prospective randomized clinical trials, 
the decision to use β-blockers in COPD patients must be made 
very carefully. However, the concept that bronchodilators (eg, 
β-agonists) and β-blockers could both decrease exacerbations 
further emphasizes the complexity of these events.
Self-management
Self-management plans empower patients with a history of 
exacerbations by teaching problem-solving skills, including 
recognition and interpretation of symptom changes, and next 
steps (eg, seeking access to appropriate care). Patient educa-
tion is a vital aspect of guided self-management in order to 
address some of the issues underlying suboptimal medica-
tion adherence, such as compromised inhaler technique 
(as described in detail elsewhere).66
Written action plans are also important components of 
self-management and could be part of PR or an existing 
chronic care program. One example currently being evalu-
ated by the Canadian Thoracic Society79 provides patients 
with advice on self- or medical-care visits, as appropriate. 
Analyses of the benefits of action plans have produced vari-
able results, mainly because of the heterogeneity in plans, 
study populations, follow-up time, and outcome measures,80 
although two separate analyses showed that self-management 
plans increased appropriate treatment81 and reduced exacer-
bation recovery time.82 Where feasible, a 24-hour telephone 
support service may reduce the number of hospitalizations.83 
Other forms of support can be considered to supplement self-
management plans (eg, Web-based consultation services or 
videophones); however, this type of home monitoring may 
be expensive to set up, and many older patients may not be 
able to master the technology. While self-management plans 
are very important, their benefits have yet to be evaluated in 
patients immediately following hospitalization or in those 
who are prone to frequent exacerbations.
Lung volume reduction surgery
Lung volume reduction surgery has been shown to improve 
the quality of life, exercise capacity, and survival in a care-
fully selected group of patients with upper-lobe predominant 
emphysema.84 The evidence suggests that patients who meet 
pre-specified criteria for surgery and undergo the procedure 
may receive an additional benefit in terms of a reduction in 
exacerbations, potentially by improving respiratory mechan-
ics and decreasing the volume of trapped air from hyperin-
flated regions of the lungs.85
Summary
Many patients with COPD delay reporting exacerbations, 
which leads to detrimental consequences to their quality of 
life.29 Severe exacerbations, usually involving hospitaliza-
tion, are associated with enormous health and socioeco-
nomic costs. Short-acting bronchodilators and oxygen are 
prescribed to relieve dyspnea, corticosteroids to decrease 
inflammation during an acute exacerbation, and appropriate 
antibiotic therapy to treat bacterial infections. A long-term 
treatment plan should include one or more available classes 
of drugs (LAAC, LABA [alone or in combination], an ICS/
LABA combination, and phosphodiesterase-4 inhibitor) that 
represent maintenance pharmacotherapies to prevent future 
exacerbations, as well as management of coexisting nonpul-
monary conditions and strategies to optimize adherence to 
inhaled medications. Supplementary PR may be important in 
preventing or delaying the recurrence of exacerbations in 
some patients after they have recovered from an acute event. 
Self-management plans, as part of PR or a chronic care 
program, may contribute to a reduction in the frequency and 
severity of exacerbations.
Conclusion
Exacerbations affect patient longevity and quality of life, 
thereby dramatically contributing to the cost of care for 
affected individuals. By helping to prevent, recognize, and 
appropriately treat these events, clinicians can have a major 
impact on the course of COPD.
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